Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS
PRINCETON,N.J. and SUZHOU,China,Dec. 13,2024-- Transcenta Holding Limited ("Transcenta") (HKEX: 06628),a global clinical stage biopharmaceutical company with fully-integrated capabilities in